PRESCIENT THERAPEUTICS LIMITED — Director's Dealing 2016

Dec 20, 2016

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

	Name of entity Prescient TherapeuticsLimited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	25November 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	-
Date of change	21December 2016
No. of securities held prior to change	200,000 Unlisted options exercisable at $0.081(8.1 cents) per option, expiring on 4 November2018
Class	Unlisted options exercisable at $0.1194 (11.94cents) per option, expiring on 21December 2019
Number acquired	247,000 unlisted options
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	200,000 Unlisted options exercisable at $0.081(8.1 cents) per option, expiring on 4 November2018247,000Unlisted options exercisable at $0.1194(11.94cents)peroption,expiringon21December 2019
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	Grant of unlisted options following shareholderapproval providedat the Company's 2016AnnualGeneral Meeting held on 30 November 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Were the interests in the securities or contracts detailedabove traded during a +closed periodwhere prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient TherapeuticsLimited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	9November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Deborah Anne Coleman(a related party of Mr Hopper)Moreglade Pty Ltd(a controlled entity of Mr Hopper)Kilinwata Investments Pty Ltd(a controlled entity of Mr Hopper)
Date of change	21December 2016

+ See chapter 19 for defined terms.

No. of securities held prior to change
Paul Edward Alexander Hopper	1,038,137Fully paid ordinary shares
Deborah Anne Coleman (a related party of MrHopper)	2,216,667 Fully paid ordinary shares
Moreglade Pty Ltd (a controlled entity of MrHopper)	2,333,334 Fully paid ordinary shares
Kilinwata Investments Pty Ltd (a controlled entityof Mr Hopper)	3,572,778Fully paid ordinary shares22,222 Listed Options
Alexandra Jane Hopper (a related party of MrHopper)	33,334 Fully paid ordinary shares
Horatia Isabelle Hopper(a related party of MrHopper)	33,334 Fullypaid ordinary shares
India Lucy Hopper(a related party of Mr Hopper)	33,334 Fully paid ordinary shares
Scarlett Augusta Wiseman Hopper(a relatedparty of Mr Hopper)	33,334 Fully paid ordinary shares
Class	Unlisted options exercisable at $0.1194 (11.94cents) per option, expiring on 21December 2019
Number acquired	1.247,000Unlistedoptionsexercisableat$0.1194 (11.94 cents) per option, expiring on21December 2019
Number disposed	2.133,336 fully paid ordinary shares (referbelow–nature of change)
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change
Paul Edward Alexander Hopper	1,038,137Fully paid ordinary shares
Deborah Anne Coleman (a related party of MrHopper)	2,216,667 Fully paid ordinary shares
Moreglade Pty Ltd (a controlled entity of MrHopper)	2,333,334 Fully paid ordinary shares
Kilinwata Investments Pty Ltd (a controlled entityof Mr Hopper)	3,572,778Fully paid ordinary shares22,222 Listed Options247,000 Unlisted options exercisable at $0.1194(11.94cents)peroption,expiringon21December 2019

+ See chapter 19 for defined terms.

Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	1.GrantofunlistedoptionsfollowingshareholderapprovalprovidedattheCompany's 2016 Annual General Meetingheld on 30 November 2016.
	2.Fully paid ordinary sharesremoved fromnoticewhichrelate to holdings of Mr Hopper'schildren, where he doesnot control therelevant holding.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issuedsecurities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Were the interests in the securities or contracts detailedabove traded during a +closed periodwhere prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient TherapeuticsLimited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Engle
Date of last notice	25November 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	-
Date of change	21December 2016
No. of securities held prior to change	300,000 Unlisted options exercisable at $0.081(8.1 cents) per option, expiring on 4 November2018
Class	Unlisted options exercisable at $0.1194 (11.94cents) per option, expiring on 21December 2019
Number acquired	370,000 unlisted options
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	300,000 Unlisted options exercisable at $0.081(8.1 cents) per option, expiring on 4 November2018370,000 Unlisted options exercisable at $0.1194(11.94cents)peroption,expiringon21December 2019
Nature of change	Grant of unlisted options following shareholder
Example: on-market trade, off-market trade, exercise of options, issue of	approval providedat the Company's 2016Annual
securities under dividend reinvestment plan, participation in buy-back	General Meeting held on 30 November 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Were the interests in the securities or contracts detailedabove traded during a +closed periodwhere prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed duringthis period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

	Name of entity Prescient TherapeuticsLimited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	1 July 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	1.Arrow Wealth Ltd (a controlled entity of Mr Yatomi-Clarke)2.Novetera Pty Ltd(a controlled entity of Mr Yatomi-Clarke)3.Alexandra Elizabeth Yatomi-Clarke
Date of change	21December 2016
No. of securities held prior to change	1.1,245,000 Fully paid ordinary shares200,000Unlistedoptionsexercisableat$0.081 (8.1 cents) per option, expiring on 4November 2018
	2.976,912 Fully paid ordinary shares70,000 Listed Options
	3.172,500 Fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	2,000,000 Fully paid ordinary shares

+ See chapter 19 for defined terms.

Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation	$0.094per share
No. of securities held after change	1.3,245,000 Fully paid ordinary shares200,000 Unlisted options
	2.976,912 Fully paid ordinary shares70,000 Listed Options
	3.172,500 Fully paid ordinary shares
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	Grant of loan fundedfully paid ordinarysharesfollowingshareholder approval provided at theCompany's 2016 Annual General Meeting held on30 November 2016.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	N/A
Interest after change	N/A

Were the interests in the securities or contracts detailed	No
above traded during a +closed periodwhere prior written
clearance was required?
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

+ See chapter 19 for defined terms.